The head of a top Brazilian health research institute says its scientists have discovered the Zika virus in urine and saliva.» Read More
People can see the prices of Obamacare coverage in their area starting Sunday. Enrollment begins Nov. 1.
A specialty drug company says it can offer a cheap alternative to compete with Turing's controversial $750 pill that sparked outrage.
Health groups called for Turing Pharmaceuticals to follow through on its promise to lower the price of a recently acquired drug.
Insurance plans can reduce costs by giving patients cash if they choose less-expensive health providers.
A study finds a connection between a heightened, but nonjudgmental, sense of awareness and a lower risk of obesity.
Shopping around for a new Medicare plan for 2016 could save you a lot of money.
Drugmaker Valeant is in dire need of a total leadership turnover, said former Medtronic CEO Bill George on Thursday.
Valeant has fallen 40 percent this week, and some traders appear to be betting on another big tumble in the next few months.
Is Valeant taking legal action against itself? The answer may come down to an odd classification known as the "variable interest entity."
Activist investor Bill Ackman made a huge bet on Valeant Pharmaceuticals Wednesday
The market for influenza vaccines globally is estimated to be about $4 billion, and growing.
The CDC recommends everyone in the U.S. older than six months receive a flu shot. Here's what you need to know.
Shareholders will get their say on two big deals: Aetna's $37B bid for Humana, and Centene's $6.3B bid for Health Net.
For Valeant investors, the bad news is that the bad news seemingly keeps on coming.
Repealing the Affordable Care Act? Unlikely. Reforming it? Possible.
Theranos only uses its finger-prick technology in one test after pressure from regulators, The WSJ reports.
Ten million people are projected to have coverage from government health exchanges by the end of 2016, a modest increase.
One of the most valuable Silicon Valley startups is under fire, according to the Wall Street Journal.
Voter initiatives in California and Ohio to control prescription med prices have ramifications for the presidential contest.
Turing Pharmaceuticals is not saying if it's actually cutting the exorbitant price of Daraprim as its CEO has promised.
Get the best of CNBC in your inbox